Heart failure & cardiomyopathies
Circulating CD19 B cell Count, Myocardial Injury and Clinical Outcomes in Patients with Heart Failure
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.57 CI 0.45–0.71Authors' conclusion
Circulating CD19 B cell counts correlated with myocardial injury and could be a feasible marker for clinical outcomes in patients with HF.
Study context
- Population
- Consecutive patients with heart failure (HF) (mean age 73, 59.6% men)
- Participants
- 395 patients
- Exposure
- Circulating lymphocyte subset counts as predictors of outcomes
- Outcome
- All-cause mortality
- Follow-up
- Median 374 days
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
Hazard ratio
0.57
CI 0.45–0.71
P < 0.0001
CD19 B cell count
HR 0.57 (CI 0.45–0.71); P < 0.0001
- C-index of CD19 B cell count for all-cause mortality, highest among lymphocyte subset counts (vs 0.69063, 0.65312, 0.60117)
- 0.73085
- C-index for all-cause mortality, basic risk factors + CD19 B cell count vs basic risk factors alone (0.7609); significant net reclassification index and integrated discrimination improvement
- 0.8000 (P = 0.0256)
Observational data: associations, not effects.
Secondary outcomes
HF-related events
| HR (CI) | P value | ||
|---|---|---|---|
| CD19 B cell countMultivariate Cox, adjusted | 0.79 (0.64–0.98) | P = 0.0293 | |
| 0.512Hazard ratio (log scale) |
Correlation of CD19 B cell count with heart-type fatty acid-binding protein
- Negative correlation (simple linear analysis), r
- −0.3669 (P < 0.0001)
Original publication
Circulating CD19 B cell Count, Myocardial Injury and Clinical Outcomes in Patients with Heart Failure. ESC Heart Fail. Published 22 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →